Hsu, Fei-Ting <br/><br/>
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.  [electronic resource] 

 -  International journal of oncology  Jul 2014 
 - 177-88 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-2423 
<br/><br/><label>Standard No.: </label>10.3892/ijo.2014.2423  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Carcinoma, Hepatocellular--pathology<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Liver Neoplasms--pathology<br/>Liver Neoplasms, Experimental<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice<br/>Mice, Nude<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Protein Serine-Threonine Kinases--metabolism<br/>Sorafenib<br/>Vorinostat<br/>Xenograft Model Antitumor Assays<br/>NF-kappaB-Inducing Kinase